Navigation Links
Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
Date:7/15/2008

NANJING, China, July 15 /PRNewswire-FirstCall/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today that it intends to release its 2008 second quarter results on Tuesday, August 5, 2008, before the market opens in the United States. Simcere's chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company's 2008 second quarter results on Tuesday, August 5, at 8 a.m. EDT (Tuesday, August 5, at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

United States toll-free dial-in number: +1.866.510.0704

United States dial-in number: +1.617.597.5362

China toll-free dial-in number: 10.800.130.0399

Hong Kong dial-in number: +852.3002.1672

Please ask to be connected to Simcere's Q2 2008 Earnings Call and provide the following passcode: 25912661. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's Web site at http://www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free dial-in number: +1.888.286.8010

United States dial-in number: +1.617.801.6888

The passcode for replay participants is: 83949361. The telephone replay also will be archived on the "Investor Relations" section of the company's Web site at http://www.simcere.com for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in the rapidly growing China market. In recent years, Simcere Pharmaceutical Group has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic anti-stroke medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 39 principal pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com.

For investor and media inquiries, please contact:

Email: ir@simcere.com

In Nanjing:

Frank Zhigang Zhao

Chief Financial Officer

Simcere Pharmaceutical Group

Tel: +86-25-8556 6666 ext. 8818

In Beijing:

Kejia Wu

Brunswick Group

Tel: +8610 6566 2256

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852 3512 5000

In New York:

Michael Guerin

Brunswick Group LLC

Tel: +1-212-333-3810


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
3. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
4. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
5. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... a redesigned, easier-to-navigate website for all six of their healthcare job boards. ... dentists, pharmacists, physical and occupational therapists, and biotechnicians, DocCafe.com and the MedJobCafe.com ...
(Date:6/22/2017)... Germany (PRWEB) , ... June 22, 2017 , ... ... is taking over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby ... all know someone who suffers from hay fever, urticaria, asthma, atopic eczema or ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... release of Limfinity® version 6.5, a content-packed update to the Limfinity® framework. , ... a larger and more diverse base of customers among labs and other businesses. ...
(Date:6/20/2017)... NEWTOWN SQUARE, Pa. , June 20, 2017 /PRNewswire/ ... technology, is pleased to announce the issuance of a ... treating gout or hyperuricemia by the U.S. Patent and ... Biotech Inc., a winner of the Buzz of Bio ... , is akin to developing non-drug approaches to ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
Breaking Biology News(10 mins):